Imara
IPO
- Headquarters
- Boston, Massachusetts
- Employees
- 11–50
- Founded
- 2016
- Business Model
- B2B
- Website
- imarainc.com
- Total Funding
- $94.0M
- Last Round
- $63.0M Series BMar 2019
About
Imara Inc. was a Boston-based clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for sickle cell disease and beta-thalassemia. Founded in 2016, Imara advanced its lead candidate tovinontrine through clinical trials before discontinuing the program in 2022. The company subsequently completed a reverse merger with Enliven Therapeutics in February 2023.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account